The FDA has approved a cutting-edge T cell immunotherapy for a rare soft tissue cancer called synovial sarcoma, which can ...

A special committee of the board of directors of 23andMe rejected an offer from the company’s CEO, Anne Wojcicki, to take the ...

Moderna cut its full-year sales guidance from $4 billion to a range of $3 billion to $3.5 billion, saying that contracting in ...

Trump often invokes the Right to Try Act. Who wouldn't want to let people who are dying and desperate try something that ...

Health officials have warned hospitals there could be a critical shortage of blood culture bottles. What does that mean for ...

HCA is seeking more money for its hospitals, while UnitedHealth is looking to hold down costs, in states including Texas and ...

It’s time for more answers about why women athletes — of all skill levels and in all sports — disproportionately experience ...

As uses of liquid biopsy grow, and new uses inch closer to the clinical setting, the risk they may exacerbate existing health ...

The FDA has approved a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, ...

Biosimilars have recently seen increased momentum in the United States, but uptake barriers remain, limiting the potential ...

Private investors are eager to back companies that run medical billing and other administrative services for hospitals and ...

In this week's podcast The Readout LOUD, STAT's Europe correspondent Andrew Joseph talks about a special report on the ...